Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

HyperCollar4D Radical Improvement of Cancer Treatment without Additional Negative Side Effects

Coordinator
Sensius BV, Netherlands
Runs
1 January 2022 to 30 June 2025
Status
Running
EU funding
€2.5m
Total cost
€8.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190101940

What the project is doing

In the project's own words, from its summary on CORDIS.

We have developed a device called HyperCollar4D that significantly increases the effectiveness of radiotherapy for head and neck (H&N) cancer. The first results on 70 patients have proven that our technology yields +50% complete response with respect to radiotherapy alone. The HyperCollar4D is based on hyperthermia: warming up the tumor to 43 C improves its sensitivity to radiotherapy. Hyperthermia yields no lasting toxicity, unlike radiotherapy and chemotherapy.

The challenge with hyperthermia is delivering it effectively (i.e., heating only the tumor and not the nearby tissues) and cost-efficiently. The HyperCollar4D is the first device to achieve effective and cost-efficient hyperthermia treatments for H&N cancer. Our technology (called thermotherapy) is protected by two patents (one granted and one filed). The HyperCollar4D design is modular, so it can be extended to add modules to treat other kinds of cancers.

Sensius is a spin-off of the Erasmus Medical Center.

Topics

Who is involved

OrganisationCityCountryRole
Sensius BVRotterdamNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI